Figure 4.

One-way sensitivity analysis of the total cost of coronary heart disease (CHD) and diabetes in 1,000 patients with schizophrenia over a 5-year time horizon. Sensitivity analyses assessing treatment of cardiometabolic adverse events (Δ) were performed on the higher-risk scenario (with olanzapine). BMI = body mass index; FG = fasting glucose; HDL = high-density lipoprotein; SBP = systolic blood pressure; TC/HDL = ratio of total cholesterol to high-density lipoprotein. Incremental cost = difference in total costs between the higher-risk and lower-risk scenarios; base case incremental cost = $539,605. All costs were in 2011 U.S. dollars.